WO2004071533A1 - 局所投与用製剤 - Google Patents
局所投与用製剤 Download PDFInfo
- Publication number
- WO2004071533A1 WO2004071533A1 PCT/JP2003/001519 JP0301519W WO2004071533A1 WO 2004071533 A1 WO2004071533 A1 WO 2004071533A1 JP 0301519 W JP0301519 W JP 0301519W WO 2004071533 A1 WO2004071533 A1 WO 2004071533A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prostate
- preparation
- urinary tract
- urethra
- lower urinary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Definitions
- the present invention relates to formulations for local administration of the prostate or urethra.
- WO 90/0855 may be directly administered by injection into the prostate, and a hydrolase suitable for inducing dissolution and regression of enlarged prostate tissue (for example, compositions for treating prostatic hypertrophy in a living mammal comprising a therapeutically effective concentration of collagenase, hyaluronidase, and the like.
- WO 01/10416 also administers an effective amount of a sustained-release preparation comprising a biodegradable polymer and at least one chemotherapeutic agent dispersed in the vicinity of cancer tissue (peritumoral tissue). Treatment methods for patients with solid cancer (eg, prostate cancer, bladder cancer, etc.) are disclosed.
- WO98 / 43555 is a biodegradable sustained release formulation for placement in the bladder through the urethra, containing a pharmaceutically active ingredient and a biodegradable pharmaceutically acceptable carrier.
- the carrier is capable of sustained release of the active ingredient into the bladder and excretable through the ureter after vigorous biodegradation.
- prostate or Z and lower urinary tract disease is one or more selected from benign prostatic hyperplasia, prostatitis, dysuria and lower urinary tract infection,
- Prophylactic and / or therapeutic drugs include luteinizing hormone, 5 reductase inhibitors, antiandrogens, antiestrogens, ⁇ -blockers, 17 ⁇ -hydroxylase inhibitors, musculin antagonists, smooth muscle relaxation Drugs, muscle relaxants,) 32 agonists, potassium channel openers, PGE2 antagonists, vanilloid receptor agonists, tachykinin receptor antagonists, denoletopioy agonists, anticholinergic agents, acetylcholinesterase inhibitors, The preparation according to (1), wherein the preparation is one or more selected from nitric oxide supply drugs and antibiotics.
- a urethral-located preparation for local administration of a urethra which comprises a prophylactic or therapeutic agent for prostate or / and lower urinary tract disease
- Prostate or / and lower urinary tract disease in which a prophylactic or therapeutic agent for non-peptidic prostate or / and lower urinary tract disease (excluding solid cancer) is locally administered to the prostate or urethra
- FIG. 1 is a graph showing the effect of local administration of the oxendron-containing micro forcepsel prepared in Example 2 into the prostate.
- Non-peptide prostate and / or lower urinary tract diseases used in the present invention include prophylactic and / or therapeutic agents for prostate disease (for example, prostate hypertrophy, and Prophylactic and therapeutic drugs for inflammation), prophylactic and therapeutic drugs for lower urinary tract diseases (for example, urinary disorders (eg, frequent urination, urinary incontinence and other urinary storage disorders, urinary discharge disorders, etc.)
- Peptide drugs are drugs that act on the prostate or lower urinary tract, such as prophylactic or therapeutic drugs for (cystitis, urethritis).
- prophylactic and / or therapeutic agents for prostatic hypertrophy include antiandrogen drugs (eg, Oxendolon, Nomegestrol, etc.), lutein honolemon drugs (eg, allylestrenol (Allylestrenol), chlormadinone acetate (Chlormadinone acetate), capron Gestonolone acid (Gestonorone caproate), osaprone acetate (Osaprone acetate, etc.), antiestrogenic drugs (eg, Mepartricin, etc.), 5 ⁇ -reductase inhibitors (eg, fenasteride, dutasteride, etc.), PA-109, THE-320, YM-31758, YM-32906, KF-20405, MK-0434, CS-891 and the like.
- antiandrogen drugs eg, Oxendolon, Nomegestrol, etc.
- lutein honolemon drugs eg, ally
- prophylactic / prophylactic treatment for prostatitis examples include new quinolone antibiotics (eg, levofloxacin, ofloxacin, tosfloxacin tosylate), macrolide antibiotics (eg, clarithromycin) and the like.
- Examples of preventive and remedy drugs for urinary excretion disorders include ⁇ -blockers such as ⁇ 1-blockers. No. Examples of ⁇ -blockers include tamsulosin, prazosin, terazosin, doxazosin, ⁇ rapidinole, indoramin, and inolemin.
- Prophylactic treatment for urinary incontinence and other urinary storage disorders include, for example, muscarinic antagonists (eg, oxiptinin hydrochloride, propiverine hydrochloride, tolterodine, darifenacinine, solifenacin, temiverine (NS-21), KRP_197, Spium etc.), smooth muscle relaxants (eg, flavoxate hydrochloride etc.), muscle relaxants
- muscarinic antagonists eg, oxiptinin hydrochloride, propiverine hydrochloride, tolterodine, darifenacinine, solifenacin, temiverine (NS-21), KRP_197, Spium etc.
- smooth muscle relaxants eg, flavoxate hydrochloride etc.
- muscle relaxants eg, flavoxate hydrochloride etc.
- agonist eg, Clenbutol
- potassium channel opener eg, ZD-0947, NS-8, KW-7158, WAY-151616, ABT-598, etc.
- PGE2 Antagonists eg, 0N0-8711 etc.
- vanilloid receptor agonists eg, regi-ferratoxin, capsaicin, etc.
- tachykinin receptor antagonists especially substance P receptor antagonists and -eurokinin A receptor antagonists
- delta-obioid agonists e.g., anticholinergic agents (e.g., temiverine (Temiverine), etc.), acetylcholinesterase inhibitors (e.g., Donepezil, Tacrine, Galantamine, Huperzine A, Physostigmine (Physo) stigmine), rivastig
- antibiotics such as Newkino
- Lon antibiotics eg, lepofloxacin, ofloxacin, tosfloxacin tosylate, etc.
- cefem antibiotics eg, cefzil, cefotiam hydrochloride, etc.
- tetracycline antibiotics eg, minomycin, etc.
- penicillin Antibiotics eg, ampicillin
- / 3 lactamase inhibitors eg, sulbactam sodium
- triazole antifungals eg, fluconazole, itraconazole, etc.
- imidazole antifungals eg, ketoconazole, etc.
- polyene macrolide antifungals for example, amphoterin-1B.
- the “prostate or Z and lower urinary tract disease prophylactic / therapeutic agent” in the “formulation for local administration of urethra-installed urethra containing the prophylactic or / and lower urinary tract disease preventive / therapeutic agent” of the present invention includes: In addition to prophylactic and therapeutic drugs for prostate disease and prophylactic and therapeutic drugs for lower urinary tract disease, prophylactic and therapeutic drugs for prostate cancer, bladder cancer and prophylactic and therapeutic drugs for urethral cancer are used. These drugs may be peptidic or non-peptidic V, preferably non-peptidic.
- prostate cancer prophylactic / therapeutic agents include antiandrogenic drugs [eg, Flutaraide, Bicalutamide, Niltamide
- LHR Hagonist for example, Leuprorelin (Leuprorelin), Buserelin (Buserelin), Triptorelin-DDS (Triptorelin-DDS), Goserelin (Goserelin-DDS), Leuprorelin-DDS (Leuprorelin-DDS) DDS (Leuprolide-DDS), Buserelin-DDS (Buserelin-DDS), Aberelix-DDS (Abarelix-DDS) Cetrorelix (Cetrorelix), Setoro Lelie box one DDS (Cetrorelix- DDS), etc.], the apoptosis-inducing drugs, phosphodi Esterase inhibitors (eg, Exisulind), microtubule polymerization inhibitors (eg, vinorelbine), differentiation inducers, immunostimulants (eg, fenretinide), 5 ⁇ - Reductase inhibitors (eg, finasteride), matrix metallo-lipase inhibitors (e
- the drug content in the preparation of the present invention varies depending on the form of the preparation, the kind of the drug, the desired pharmacological effect and the duration of the effect, and is usually about 0.1 to 99% by weight based on the whole preparation. %, Preferably about 0.5 to 80% by weight. / 0 , more preferably about 1 to 50% by weight.
- Examples of the dosage form of the preparation of the present invention include pellets for embedding, microcapsules, emulsions, injections, suspensions, and transurethral preparations (eg, cylindrical, sheet, coil, and stent types). is there. These preparations may be sustained-release preparations, and are preferably sustained-release microcapsules and urethral placement preparations (stent-type preparations).
- a polymer can be used as a base.
- the polymer there are a biodegradable polymer and a biodegradable polymer.
- the use of a biodegradable polymer is preferable because it does not need to be removed after administration and does not accumulate in the living body.
- Biodegradable polymers include, for example, ⁇ -hydroxycarboxylic acids (eg, glycolenoic acid, lactic acid, etc.), hydroxydicarbonic acids (eg, malic acid, etc.), hydroxytricanoleponic acid (eg, cunic acid) Etc.), a polymer having a free carboxyl group, a copolymer or a mixture thereof; poly-a-cyanoacrylate; polyamino acid (eg, poly-g-benzinole-L-glutamic acid) Etc.); maleic anhydride copolymers (eg, styrene-maleic acid copolymers) and the like are used.
- ⁇ -hydroxycarboxylic acids eg, glycolenoic acid, lactic acid, etc.
- hydroxydicarbonic acids eg, malic acid, etc.
- hydroxytricanoleponic acid eg, cunic acid
- a polymer having a free carboxyl group a cop
- the type of polymerization may be random, block, 1 / of graft, or deviation.
- a-hydroxy acids, hydroxydicarboxylic acids or hydroxytrisulfonic acids have an optically active center in the molecule, any of D-, L-, and DL-forms are used. be able to.
- a monohydroxycarboxylic acid polymer preferably a lactic acid-glycolic acid polymer
- an ester thereof, a poly- ⁇ - cyanoacrylate ester and the like are preferable. More preferably, it is a lactic acid-dalicholate polymer.
- the set composition ratio (mol 0/0) is preferably 100Zeta0 ⁇ 40 / 60, particularly preferably 100 / 0-50 / 50.
- the weight-average molecular weight of the lactic acid-glycolic acid polymer is usually about 3,000 to about 50,000, preferably about 4,000 to about 40,000, and more preferably about 5,000 to about 30,000. , 000.
- the dispersity is usually preferably about 1.2 to about 4.0, and more preferably about 1.5 to 3.5.
- the weight-average molecular weight, number-average molecular weight and dispersity in the present specification mean that the weight-average molecular weight is 1.110,000, 707,000, 354,000, 189,000, 156,000, 98,900, 66. , 437, 37, 200, 17, 100, 9, 830, 5,870, 2,500, 1,303, 500
- Measured by gel permeation chromatography (GPC) using 14 kinds of polystyrene as reference materials Means the calculated molecular weight in terms of polystyrene and the calculated degree of dispersion.
- GPC gel permeation chromatography
- the biodegradable polymer is dissolved in a mixed solvent of acetone and methanol, and the solution is titrated with phenolphthalein as an indicator using an alcoholic hydroxylamine solution to calculate the number average molecular weight by terminal group determination. did.
- this is referred to as a number average molecular weight by terminal group quantification.
- the number average molecular weight determined by end group quantification is an absolute value
- the number average molecular weight determined by GPC measurement depends on the analysis or analysis conditions (e.g., mobile phase type, column type, reference material, selection of slice width, Since it is a relative value that fluctuates depending on the selection of a baseline, etc., it is difficult to make a clear numerical value.
- a free carboxy group is synthesized from lactic acid and glycolic acid by a noncatalytic dehydration polycondensation method.
- the number average molecular weight determined by GPC and the number average molecular weight determined by terminal group quantification are almost the same.
- the approximate agreement with the lactic acid-glycolic acid polymer is based on the number-average molecular
- the amount is in the range of about 0.2 to about 1.5 times the number average molecular weight measured by GPC, preferably in the range of about 0.3 to about 1.2 times.
- Lactic acid-glycolic acid polymer is, for example, a catalyst-free dehydration polycondensation from lactic acid and glycolic acid (Japanese Patent Application Laid-Open No. 61-28521) or a catalyst derived from lactide and a cyclic substance such as glycolide. It can be produced by ring-opening polymerization using Encyclopedic Handbook of Biomaterials and Bioengmeering Part A: Materials, Volume 2, Marcel Dekker, Inc., 1995.
- the polymer synthesized by ring-opening polymerization is a polymer having no carboxyl group, but a polymer obtained by chemically treating the polymer to form a free carboxyl group at the end (Journal No. Control System). Nored Releases (J. Controlled Release), 41, 2
- the lactic acid-glycolic acid polymer having a free carboxyl group at the terminal can be produced without any problem by a known production method (for example, a non-catalytic water polycondensation method, see Japanese Patent Application Laid-Open No. 61-28521). Further, a polymer having a free carboxy group not specified at the terminal can be produced by a known production method (for example, see WO94 / 15587).
- lactate-glycolic acid polymer whose terminal has been converted into a free hydroxyl group by a chemical treatment after ring-opening polymerization is, for example, Boehringer Ingelheim (Boehringer
- Ingelheira KG may be used.
- biodegradable polymers may be used alone or as a mixture of two or more.
- the biodegradable polymer may contain a polyvalent metal.
- the polyvalent metal is not particularly limited as long as it is a compound that does not adversely affect the living body, and examples of the metal species include divalent (eg, iron, zinc, copper, calcium, magnesium, anolemmium, tin, Polyvalent metals (preferably zinc, etc.) such as manganese, etc., trivalent (eg, iron, anoremium, manganese, etc.) and tetravalent (eg, tin, etc.).
- Preferred specific examples of the polyvalent metal include, for example, iron, aluminum, zinc, calcium, and magnesium.
- a particularly preferred specific example of the polyvalent metal includes zinc.
- the amount of the biodegradable polymer in the preparation of the present invention is usually about 5 to about 99.9% by weight, more preferably about 20 to about 99.5% by weight, and particularly preferably about 50 to about 99.5% by weight. 9.9 weight ° / 0 .
- the form of the sustained-release preparation of the present invention is not particularly limited, but it is considered that an implant, a microcapsule injection, etc. are possible.
- the sustained-release period is long, and the injection preparation using microcapsules with a small burden on the patient. Is preferred. It may also be in the form of microcapsules or sheets, rings, cylinders, coins, etc., for placement in the urethra.
- Commonly used urethral stents eg, soluble self-expandable stents, BIONIX: Angiomed Memotherm, Medicon Corporation: Memocus, Abuco Corporation, etc.
- BIONIX Angiomed Memotherm
- Medicon Corporation Memocus, Abuco Corporation, etc.
- a biodegradable urethral stent for example, a soluble self-etaspandapult stent, BIONIX, etc.
- a urethral stent M formulation capable of sustained release of the drug
- a drug-containing porous material It is a urethral stent-type preparation coated with ceramics and polymers that can release the drug over time.
- a method for producing the preparation of the present invention as a sustained-release preparation containing a biodegradable polymer, for example, a micro-oral capsule (hereinafter sometimes referred to as a microsphere preparation) will be exemplified.
- an organic solvent solution in which the drug is dissolved or an organic solvent suspension in which the drug is dispersed is prepared so as to have the weight ratio shown in the above-mentioned amount.
- the organic solvent include halogenated hydrocarbons (eg, dichloromethane, chlorophonolem, dichloroethane, trichloroethane, carbon tetrachloride, etc.), ethenoles (eg, ethyl ether, isopropyl ether, etc.), fatty acid esters (eg, acetic acid) Ethyl, butyl acetate, etc.), aromatic hydrocarbons (eg, benzene, toluene, xylene, etc.), alcohols (eg, ethanol, methanol, etc.), and acetonitrile.
- halogenated hydrocarbons eg, dichloromethane, chlorophonolem, dichloroethane, trichloroethane, carbon
- dichloromethane is preferable as the halogenated hydrocarbon
- ethanol and methanol are preferable as the alcohol.
- An additive may be added to the above organic solvent solution.
- solubilizers for keeping the stability and solubility of the drug such as carbonic acid, oxalic acid, citric acid, phosphoric acid, and hydrochloric acid, sodium hydroxide, arginine, and lysine. May be added.
- a drug stabilizing agent such as albumin, gelatin, citric acid, sodium ethylenediaminetetraacetate, dextrin, sodium bisulfite, polyethylene glycol, or the like, or a commonly used preservative such as Benzoic acid esters (eg, methyl paraben, propyl paraben, etc.), benzinole alcohol, chloroptanol, thimerosal, etc. may be added.
- Benzoic acid esters eg, methyl paraben, propyl paraben, etc.
- benzinole alcohol eg. benzinole alcohol
- chloroptanol thimerosal, etc.
- the concentration of the biodegradable polymer in the organic solvent solution varies depending on the molecular weight of the biodegradable polymer and the type of organic solvent.For example, when dichloromethane is used as the organic solvent, it is generally about 0. 5 to about 7 0% by weight, more preferably from about 1 to about 6 0 wt 0/0, particularly preferably selected from about 2 to 5 0 Tadashiryou%.
- the volume of the aqueous phase is generally about 1 to about 100,000 times, preferably about 5 to about 5,000 times, particularly preferably about 10 to 100 times the volume of the oil phase. Double to about 20000 times.
- An emulsifier may be added to the above external water phase.
- any emulsifier can be used as long as it can form a stable ⁇ ZW emulsion.
- anionic surfactants such as sodium oleate, sodium stearate, and sodium laurinole sulfate
- nonionic surfactants polyoxyethylene sorbitan fatty acid ester [Tween 80, Tween (Tween) 60, Atlas Powder Co., Ltd.), polyoxyethylene castor oil derivatives [HC0-60, HC0-50, Nikko Chemicals, etc.)
- polyvinylpyrrolidone polyvinyl alcohol, carboxymethinole senorelose, lecithin, gelatin, hyaluronic An acid or the like is used.
- the concentration of use preferably at about 0. 0 range 1 ⁇ 1 ⁇ weight 0/0, more preferably used at about 0. 0 5 to about 5 wt ° / 0 range.
- An osmotic pressure regulator may be added to the above external aqueous phase.
- the osmotic pressure adjusting agent may be any agent that exhibits an osmotic pressure when used as an aqueous solution.
- osmotic pressure adjusting agent examples include polyhydric alcohols, monohydric alcohols, monosaccharides, disaccharides, oligosaccharides, amino acids, and derivatives thereof.
- polyhydric alcohols examples include dihydric alcohols such as glycerin, pentahydric alcohols such as arabitol, xylitol, and additol, and hexahydric alcohols such as mannitol, sorbitol and zunoresitol. . Of these, hexahydric alcohols are preferred, and mannitol is particularly preferred.
- Examples of the above monohydric alcohols include methanol, ethanol, and isopropyl alcohol, and among them, methanol is preferable.
- Examples of the above-mentioned monosaccharides include pentoses such as arabinose, xylose, lipose, and 2-deoxylipose, and hexoses such as glucose, glucosyl, galactose, manose, sorbose, rhamnose, and fucose. Carbohydrates are preferred.
- oligosaccharide for example, trisaccharides such as maltotriose and raffinose sugars, and tetrasaccharides such as stachyose are used, and among them, trisaccharides are preferable.
- disaccharides and oligosaccharides for example, dalcosamine, galactosamine, glucuronic acid, galataturonic acid and the like are used.
- any L-form amino acid can be used, and examples thereof include glycine, leucine, and arginine. Of these, L-anoleginine is preferred.
- osmotic pressure regulators may be used alone or as a mixture.
- osmotic pressure adjusting agents are used at a concentration such that the osmotic pressure of the external aqueous phase is about 50 to about 5 times, preferably about 1/25 to about 3 times the osmotic pressure of physiological saline.
- a method for removing water and the organic solvent As a method for removing water and the organic solvent, a method known per se or a method analogous thereto is used. For example, a method of evaporating water and an organic solvent at normal pressure or gradually reducing the pressure while stirring with a propeller type stirrer or a magnetic stirrer, or adjusting the degree of vacuum using a rotary evaporator or the like. You And a method of evaporating the organic solvent.
- microcapsules thus obtained are separated by centrifugation or filtration, and then the drug, drug-retaining substance, emulsifier, etc. adhering to the surface of the microcapsules are washed several times with distilled water and distilled again. Disperse in water and freeze-dry.
- an anti-agglomeration agent may be added to prevent aggregation of the particles.
- the aggregation inhibitor include water-soluble polysaccharides such as mannitol, ratatose, glucose, starches (eg, corn starch), amino acids such as glycine, and proteins such as fibrin and collagen. Among them, Manni Tonore is preferred.
- heating may be performed under reduced pressure so that the microcapsules do not fuse with each other to remove water and the organic solvent from the micro force capsule.
- the polymer is heated at a temperature slightly higher than the midpoint glass transition temperature of the biodegradable polymer determined by a differential scanning calorimeter under the condition of a heating rate of 10 to 20 ° C per minute. . More preferably, heating is performed within a temperature range about 30 ° C. higher than the midpoint glass transition temperature of the biodegradable polymer.
- the temperature range is preferably higher than the midpoint glass transition temperature and higher by 10 ° C than the midpoint glass transition temperature, and more preferably, the midpoint glass is used.
- the heating time varies depending on the amount of microcapsules, etc., but generally from about 12 hours to about 168 hours, preferably about 24 hours, after the microforce has reached a predetermined temperature. From about 120 hours to about 120 hours, particularly preferably from about 48 hours to about 96 hours.
- the heating method is not particularly limited as long as the assembly of micro force cells can be uniformly heated.
- the heating and drying method for example, a method of heating and drying in a constant temperature bath, a fluidized tank, a moving tank or a kiln, a method of heating and drying with a microwave, and the like are used. Of these, the method of heating and drying in a thermostat is preferred.
- the removal of water and organic solvent in microcapsules can be performed by a method using a supercritical fluid (such as CO 2 ).
- a supercritical fluid such as CO 2
- a coacervation agent is added to an organic solvent solution or a suspension of a biodegradable polymer containing water or a drug described in the above-mentioned (I) in-water drying method. Add slowly with stirring to precipitate and solidify the microcapsules.
- the coacervation agent is selected from about 0.01 to 1,000 times, preferably about 0.05 to 500 times, particularly preferably about 0.1 to 200 times the oil phase volume. It is.
- the coacervation agent is not particularly limited as long as it does not dissolve both the bioactive compound and the biodegradable polymer, such as a polymer, a mineral oil or a vegetable oil compound that is miscible with an organic solvent. Is not done. Specifically, for example, silicon oil, sesame oil, soybean oil, corn oil, cottonseed oil, coconut oil, linseed oil, mineral oil, n-hexane, n-heptane and the like are used. These may be used as a mixture of two or more.
- microcapsules thus obtained are collected, they are repeatedly washed with heptane or the like to remove the drug and the coacervation agent other than the biodegradable polymer, and dried under reduced pressure.
- freeze-drying, further heating drying, and desolvation with a supercritical fluid may be performed.
- an organic solvent solution of the biodegradable polymer containing the drug described in the above (I) in-water drying method is used for spray drying using a nozzle with a nozzle.
- (Spray dryer) Sprays water and organic solvent in atomized droplets in a very short time to prepare a micro force cell.
- the nozzle include a two-fluid nozzle type, a four-fluid nozzle type, a pressure nozzle type, and a rotating disk type. Thereafter, if necessary, washing may be carried out in the same manner as described in the above-mentioned in-water drying method (I), followed by freeze-drying, heating drying, and desolvation by a supercritical fluid.
- an organic solvent solution or suspension of a biodegradable polymer containing the drug described in the underwater drying method of the manufacturing method (I) of the micro force psenole agent for example, The organic solvent and water are evaporated to dryness while adjusting the degree of vacuum using a rotary evaporator, and then dried using a jet mill. It can be crushed into fine powder.
- the pulverized fine powder is washed in the same manner as described in the underwater drying method of the microcapsule preparation method (I), followed by lyophilization, and further drying by heating, desolvation by supercritical fluid, etc. You can go.
- drug release can be controlled according to the decomposition rate of the biodegradable polymer used and the type and amount of additives.
- the sustained release preparation can be administered to the prostate or the urethra as it is or as a raw material as a raw material in various dosage forms.
- these may be dispersing agents (eg, surfactants such as Tween 80, HC0-60, etc .; sodium hyaluronate, carboxymethyl cellulose, sodium alginate, etc.).
- Aqueous suspending agents together with preservatives eg, methyl paraben, propinoleparaben, etc.
- tonicity agents eg, sodium chloride, mannitol, sorbitol, pudose, proline, etc.
- they can be dispersed with vegetable oils such as sesame oil and corn oil to give sustained-release injections that can be actually used as oily suspensions.
- the particle size of the sustained-release preparation may be within a range that satisfies the dispersibility and the needle penetration property.
- the average particle diameter is about 0.1 to 30. 0 ⁇ m, preferably in the range of about 0.5 to 150 ⁇ m, more preferably in the range of about 1 to 100 ⁇ .
- a method for producing the preparation of the present invention as a sustained-release preparation containing a biodegradable polymer for example, a cylindrical, sheet, coil, or stent type is exemplified.
- An organic solvent solution of the biodegradable polymer, as the c organic solvent to make an organic solvent solution or organic solvent suspension prepared by dispersing and dissolving the drug in so that such weight ratios shown in the amount of the for example, halogenated hydrocarbons (eg, dichloromethane, chlorophonolem, dichloroethane, trichloroethane, carbon tetrachloride, etc.), ethers (eg, ethyl ether, isopropyl ether, etc.), fatty acid esters (eg, acetic acid) Ethyl, butyl acetate, etc.), aromatic hydrocarbons (eg, benzene, toluene, xylene, etc.), alcohols (eg, ethanol,
- An additive may be added to the above organic solvent solution in order to change film properties and moldability.
- the additives include polyethylene glycolones, 2-methacryloyloxyshetyl phosphorylcholine (MPC) polymer, n-butyl methacrylate (BMA) polymer, copolymer of MPC and BMA, segment Polyurethanes, polysulfones, polyvinylidene fluorides, polyamides, cellulose acetates, polyimides, cunic acid derivatives (for example, triethylcunic acid, acetinoletriethylculic acid, tributylcunic acid, etc.), phthalic acid Derivatives (for example, getyl phthalnoleic acid, dibutyl phthalic acid, etc.), yacetin, polyvinylamine 80 and the like.
- MPC 2-methacryloyloxyshetyl phosphorylcholine
- BMA n-butyl me
- An additive may be added to the above organic solvent solution.
- the additive include solubilizing agents for maintaining stability and solubility of the drug, such as carbonic acid, oxalic acid, citric acid, phosphoric acid, and hydrochloric acid, sodium hydroxide, arginine, lysine, and salts thereof. May be added.
- a drug stabilizing agent a polyol compound such as anolebumin, gelatin, citric acid, sodium ethylenediaminetetraacetate, dextrin, sodium bisulfite, or polyethylene glycol, or paraoxybenzoic acid which is generally used as a preservative is used. Estenoles (eg, methylparaben, propylparaben, etc.), benzyl alcohol, chlorobutanol, thimerosanole and the like may be added.
- the concentration of the biodegradable polymer in the organic solvent solution varies depending on the molecular weight of the biodegradable polymer and the type of organic solvent.For example, when dichloromethane is used as the organic solvent, it is generally about 0.5 to about 70% by weight, more preferably about 1 to about 60% by weight, particularly preferably about 2 to about 50% by weight.
- the solution of the above drug and polymer in an organic solvent can be prepared by a known manufacturing method (eg, casting method, stretching method, etching method, sintering method, etc.) into a tube, sheet, coil, or stent. Can be formed.
- a known manufacturing method eg, casting method, stretching method, etching method, sintering method, etc.
- the sustained-release preparation may be a sterile preparation, in which case, for example, a method of sterilizing the production process, a method of sterilizing with gamma ray, a method of combining these methods, or a method of adding a preservative, etc. There is no particular limitation.
- the formulation of the present invention has low toxicity, it can be used as a drug safe for mammals (eg, humans, cattle, pigs, dogs, cats, mice, rats, rabbits, etc.).
- the formulation of the present invention may be used for prostate disease (eg, benign prostatic hyperplasia, prostate cancer, prostatitis, etc.), lower urinary tract disease (disease in the bladder and Z or urethra, eg, dysuria (eg, frequent urinary incontinence, Urgency due to overactive bladder, impaired urine storage such as hypotonic bladder due to overactive bladder, urinary dysfunction, bladder dysfunction, difficulty urinating, urinary pain, urinary obstruction, etc., lower urinary tract infection, bladder cancer , Urethral cancer, etc.).
- prostate disease eg, benign prostatic hyperplasia, prostate cancer, prostatitis, etc.
- lower urinary tract disease disease in the bladder and Z or urethra
- dysuria eg, frequent urinary incontinence,
- dysuria examples include prostatic hypertrophy, bladder neck obstruction, neurogenic bladder, diabetes, surgery, dysuria due to hypotonic bladder, and more specifically, hypotonic bladder due to benign prostatic hyperplasia, Hypotonic bladder due to diabetes, hypotonic bladder due to diabetic neuropathy, idiopathic hypotonic bladder (including aging), hypotonic bladder due to multiple sclerosis, hypotonic bladder due to Parkinson's disease, spinal cord injury Hypotonic bladder, hypotonic bladder after surgery, hypotonic bladder due to cerebral infarction, neuropathic bladder due to diabetes, neuropathic bladder due to diabetic neuropathy, neuropathic bladder due to multiple sclerosis, parki Urinary dysfunction due to neuropathic bladder due to Nsonson's disease, neuropathic bladder due to spinal cord injury, and neurogenic bladder due to cerebral infarction.
- the preparation of the present invention is particularly useful as a prophylactic / therapeutic agent for prostatic menopathy or associated dysuria.
- the dosage of the preparation of the present invention varies depending on the type and content of the drug as the main drug, the dosage form, the duration of drug release, the target disease, the target animal, and the like, but may be any effective amount of the drug.
- the dose of the active ingredient per dose is preferably in the range of about 0.001 mg to lg per adult, more preferably about 0.1 mg / lg. ⁇ It can be appropriately selected from the range of lmg to 50 mg.
- the dose of the preparation of the present invention per dose can be suitably selected from the range of preferably about 0.5 mg to 10 g, more preferably about 5 mg to 5 g, per adult.
- the frequency of administration is once every few weeks, once a month, or once every few months (eg, every three months, four months, six months, etc.). It can be appropriately selected depending on the duration of drug release, target disease, target animal, and the like.
- the administration method of the preparation of the present invention is transurethral or percutaneous administration from the perineum, but is not limited thereto.
- systemic administration eg, subcutaneous administration, intramuscular administration, etc.
- 17 ⁇ -hydroxylase inhibitors eg, CB-7598, ⁇ -116, etc.
- local or systemic administration to the testis or adrenal gland eg, subcutaneous, intramuscular, etc. is also effective. is there.
- the preparation of the present invention can be advantageously used for patients who are difficult or impossible to treat with internal medicine such as bedridden, dementia, throat / esophagus disease, gastrointestinal disease, eating and swallowing disorders, and surgery. Can be.
- the formulations of the present invention include estrogen agents (eg, getylstilyl vesdro-1 ⁇ / etc.), LH-RH agonists (eg, goserelin acetate, leuprorelin acetate, etc.) LH-RH antagonists (eg, Ab arelix, Ce trore 1ix), 17a hydroxylase inhibitor (eg, CB-7598, YM-116, etc.) and the like, and the therapeutic effect can be expected to be improved.
- estrogen agents eg, getylstilyl vesdro-1 ⁇ / etc.
- LH-RH agonists eg, goserelin acetate, leuprorelin acetate, etc.
- LH-RH antagonists eg, Ab arelix, Ce trore 1ix
- 17a hydroxylase inhibitor eg, CB-7598, YM-116, etc.
- Example 1 Example 1
- Powder containing 2 mg of tamsulosin hydrochloride (based on Yamanouchi Pharmaceutical formulation) 1.6 g of lactic acid-glycolic acid copolymer (lactic acid / glycolic acid, 75/25 (mol%): weight average molecular weight , 12,000: number average molecular weight, 3,500: Wako Pure Chemical Industries) 0.4 g dissolved in dichloromethane 5 mL?
- the resulting solution was added to the mixture to form a dispersion.
- 0 - 1 weight dispersion previously adjusted to 15 ° C under this 0 /.
- Polyvinyl alcohol aqueous solution Injected into 40 OmL, using a turbine type homomixer, 7,000 rpm With s ZoZw emulsion.
- the s ⁇ / W emulsion was stirred at room temperature for 3 hours to evaporate dichloromethane, solidify the oil phase, and then use a centrifuge.
- Oxendron Takeda Pharmaceutical
- lactic acid-glycolic acid copolymer lactic acid Z glycolic acid, 75Z25 (mol%): weight average molecular weight, about 10,500: number average molecular weight, about 5,000: sum Kogaku Pharmaceutical Co., Ltd.
- 1.8 g was dissolved in 2 mL of dichloromethane. This solution was poured into 500 mL of a 0.1% by weight aqueous solution of polyvinyl alcohol, and an O / W emulsion was prepared using a turbine-type homomixer at 7,000 rpm.
- the OZW emulsion was stirred at room temperature for 3 hours to evaporate dichloromethane and solidify the oil phase, and then collected at 3,000 rpm using a centrifuge. This was dispersed again in distilled water, and further centrifuged to wash free drug and the like. The collected microcapsules were re-dispersed by adding distilled water in which a small amount of mannitol was dissolved, and then freeze-dried to obtain 1.4 g of powder having a 21% mannitol content. The recovery rate was 55.3% .Example 3
- Oxendron (Takeda Pharmaceutical) 50 mg, lactic acid-glycolic acid copolymer (lactic acid dalicholate, 7525 (mol%): weight average molecular weight, about 10,500: number average molecular weight, about 5,000: (Wako Pure Chemical Industries) 500 mg was added to a solution of dichloromethane in 0.5 mL to prepare a solution. This solution was placed on a release liner placed on a flat casting table and stretched to a thickness of about 0.9 mm. Next, the mixture was allowed to stand at room temperature in a cylindrical state together with the liner to evaporate dichloromethane to obtain a preparation in the form of a cylindrical sheet. The oxendron-containing sheet can be placed on the urethra near the prostate, for example, wound around a urethral stent. Test example 1
- the oxendone-containing mic-mouth capsule prepared in Example 2 was dispersed in physiological saline, and the microcapsules having lmg as oxendron were prepared in a male rat (10-week-old, CD (SD) IGS, Charles River) prostate. They were injected intra- or intra-thigh muscle. One week after administration, the left and right prostates were excised, weight-corrected, and the total weight of the left and right prostates was compared.
- FIG. 1 clearly shows a decrease in prostate weight in the group administered locally in the prostate, indicating that the preparation for local administration of the present invention is an excellent preparation for treating benign prostatic hyperplasia and the like. Individuals available for industrial use
- the preparation of the present invention can be directly administered to the prostate or the urethra, it can exert its effect with a smaller amount of drug than conventional oral preparations and injections, so that side effects when the drug circulates throughout the body can be reduced. It becomes possible.
- a sustained-release preparation a single administration is expected to maintain a long-term therapeutic effect. That is, once administration of the therapeutic agent of the present invention directly to the prostate or the urethra improves diseases such as benign prostatic hyperplasia, prostate cancer, prostatitis, dysuria, bladder cancer, urethral cancer, and lower urinary tract infection. Achieved over time.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/001519 WO2004071533A1 (ja) | 2003-02-14 | 2003-02-14 | 局所投与用製剤 |
AU2003207089A AU2003207089A1 (en) | 2003-02-14 | 2003-02-14 | Preparation for topical administration |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/001519 WO2004071533A1 (ja) | 2003-02-14 | 2003-02-14 | 局所投与用製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004071533A1 true WO2004071533A1 (ja) | 2004-08-26 |
Family
ID=32866111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/001519 WO2004071533A1 (ja) | 2003-02-14 | 2003-02-14 | 局所投与用製剤 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003207089A1 (ja) |
WO (1) | WO2004071533A1 (ja) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040150A1 (en) * | 1995-06-07 | 1996-12-19 | Merck & Co., Inc. | Treatment and prevention of prostatic disease |
WO1999021558A2 (en) * | 1997-10-28 | 1999-05-06 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
WO1999021508A1 (en) * | 1997-10-28 | 1999-05-06 | Vivus, Inc. | Administration of active agents, including 5-ht receptor agonists and antagonists, to treat premature ejaculation |
WO2000004027A1 (en) * | 1998-07-16 | 2000-01-27 | Abbott Laboratories | Piperazynil pyrimidine dione compounds selective for adrenoceptors |
WO2000007604A1 (en) * | 1998-08-03 | 2000-02-17 | Wheeler Ronald E | Prostate formula |
WO2000012075A1 (en) * | 1998-09-01 | 2000-03-09 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
WO2000018391A1 (fr) * | 1998-09-30 | 2000-04-06 | Takeda Chemical Industries, Ltd. | Medicaments qui ameliorent le pouvoir de vidange de la vessie |
WO2000045795A2 (en) * | 1999-02-05 | 2000-08-10 | Cipla Limited | Topical sprays comprising a film forming composition |
WO2000048636A1 (en) * | 1999-02-18 | 2000-08-24 | Inpharma S.A. | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients |
EP1123705A1 (en) * | 2000-02-09 | 2001-08-16 | Pfizer Products Inc. | Pharmaceutical combinations for treating lower urinary tract disfunctions |
WO2002083142A1 (fr) * | 2001-04-13 | 2002-10-24 | Yamanouchi Pharmaceutical Co., Ltd. | Nouvelle utilisation du derive arylethenesulfonamide |
-
2003
- 2003-02-14 WO PCT/JP2003/001519 patent/WO2004071533A1/ja not_active Application Discontinuation
- 2003-02-14 AU AU2003207089A patent/AU2003207089A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040150A1 (en) * | 1995-06-07 | 1996-12-19 | Merck & Co., Inc. | Treatment and prevention of prostatic disease |
WO1999021558A2 (en) * | 1997-10-28 | 1999-05-06 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
WO1999021508A1 (en) * | 1997-10-28 | 1999-05-06 | Vivus, Inc. | Administration of active agents, including 5-ht receptor agonists and antagonists, to treat premature ejaculation |
WO2000004027A1 (en) * | 1998-07-16 | 2000-01-27 | Abbott Laboratories | Piperazynil pyrimidine dione compounds selective for adrenoceptors |
WO2000007604A1 (en) * | 1998-08-03 | 2000-02-17 | Wheeler Ronald E | Prostate formula |
WO2000012075A1 (en) * | 1998-09-01 | 2000-03-09 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
WO2000018391A1 (fr) * | 1998-09-30 | 2000-04-06 | Takeda Chemical Industries, Ltd. | Medicaments qui ameliorent le pouvoir de vidange de la vessie |
WO2000045795A2 (en) * | 1999-02-05 | 2000-08-10 | Cipla Limited | Topical sprays comprising a film forming composition |
WO2000048636A1 (en) * | 1999-02-18 | 2000-08-24 | Inpharma S.A. | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients |
EP1123705A1 (en) * | 2000-02-09 | 2001-08-16 | Pfizer Products Inc. | Pharmaceutical combinations for treating lower urinary tract disfunctions |
WO2002083142A1 (fr) * | 2001-04-13 | 2002-10-24 | Yamanouchi Pharmaceutical Co., Ltd. | Nouvelle utilisation du derive arylethenesulfonamide |
Non-Patent Citations (8)
Title |
---|
AITANI NOBUYUKI ET AL.: "Zenritsusem hidai-sho ni taisuru keinyodoteki ethanol chunyu ryoho;yukosei ni kansuru tokeigakuteki kento", NIHON HINYOKI KAGAKUKAI ZASSHI, vol. 93, no. 2, 2002, pages 233, XP002904418 * |
AITANI NOBUYUKI ET AL.: "Zenritsusen hidai-sho ni taisuru ethanol chunyu ryoho", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 60, no. 11, 2002, pages 402 - 407, XP002904416 * |
AITANI NOBUYUKI ET AL.: "Zenritsusen hidai-sho ni taisuru keinyodoteki ethanol chunyu ryoho;1-nengo seiseki no kento", NIHON HINYOKI KAGAKUKAI ZASSHI, vol. 93, no. 3, 2000, pages 254, XP002904419 * |
AMANO HIROYUKI ET AL.: "Kyokusho shinun-sei zenritsusegan ni taisuru musui ethanol chunyu ryoho no keiken", JAPANESE JOURNAL OF UROLOGICAL SURGERY, vol. 14, no. SPECIAL EXTRA ISSUE, 2001, pages 480, XP002904421 * |
KOGA YASUTSUGU ET AL.: "Hormone huo-sei zeritsusengan ni taisuru musui ethanol no chokusetsu chunyu koka no kisoteki kento", NIHON HINYOKI KAGAKUKAI ZASSI, vol. 93, no. 2, 2002, pages 333, XP002904422 * |
NAKAMURA R. ET AL.: "Anti androgen TSAA-291.I.anti androgenic effects of a new steroid TSAA-291 (16beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives", ACTA ENDOCRINOLOGICA, vol. 92, no. 229, 1979, pages 2 - 23, XP002904420 * |
RUFFOLO R.R.JR. ET AL.: "Andrenoceptor pharmacology:urogenital applications", EUROPEAN UROLOGY, vol. 36, no. SUPPL.1, 1999, pages 17 - 22, XP009021668 * |
SHIMIZU TOMOKAZU ET AL.: "Inu zenritsusen ni taisuru musui ethanol chunyugo no byori soshikigakuteki henka ni tsuiteno kento", THE NISHINIHON JOURNAL OF UROLOGY, vol. 64, November 2002 (2002-11-01), pages 133, XP002904417 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003207089A1 (en) | 2004-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69333817T2 (de) | Leuprorelinpräparat mit verzögerter Wirkstoffabgabe | |
US8715622B2 (en) | Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof | |
JP5860300B2 (ja) | 徐放性組成物およびその製造法 | |
JP5622760B2 (ja) | 乳酸重合体及びその製造方法 | |
EP0754034B1 (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules | |
WO1999036099A1 (fr) | Compositions a liberation controlee, leur procede de fabrication et leur utilisation | |
CN101163464A (zh) | 优选含有PEG和PLG混合物的控制释放GnRH的聚合物植入物 | |
ES2391460T5 (es) | Un procedimiento para producir una microcápsula de liberación sostenida | |
D’Mello et al. | Polymeric nanoparticles for small-molecule drugs: biodegradation of polymers and fabrication of nanoparticles | |
SK15602003A3 (sk) | Prípravok s regulovaným uvoľňovaním a spôsob jeho výroby | |
PT1532985T (pt) | Processo de produção de uma composição de libertação sustentada | |
JPH10273447A (ja) | 徐放性マイクロスフィア、その製造法および用途 | |
JPH08259460A (ja) | 徐放性製剤の製造法 | |
Schaefer et al. | Effect of tricaprin on the physical characteristics and in vitro release of etoposide from PLGA microspheres | |
JPH11269094A (ja) | 徐放性組成物、その製造法および用途 | |
JP6472730B2 (ja) | 徐放性製剤 | |
US20120121510A1 (en) | Localized therapy following breast cancer surgery | |
JP3490171B2 (ja) | 生体内分解性ポリマーの末端カルボキシル基におけるエステル | |
JPH10203966A (ja) | 徐放性マイクロカプセルおよびその製造法 | |
JP2004532207A (ja) | エコー源性ポリマーのマイクロカプセルおよびナノカプセル、ならびにその製造方法およびその使用 | |
WO2004071533A1 (ja) | 局所投与用製剤 | |
JPH11269097A (ja) | 新規な微粒子、その製造法および用途 | |
JPH06293636A (ja) | 微粒子製剤およびその製造法 | |
JP3524195B2 (ja) | 徐放性製剤用基剤 | |
JP3902518B2 (ja) | 徐放性組成物用乳酸−グリコール酸重合体の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |